Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

The Board of Directors of Aiforia Technologies Plc decided on new stock option plan

Aiforia Technologies

The Board of Directors of Aiforia Technologies Plc decided on new stock option plan

Aiforia Technologies Plc, Company Announcement, December 19, 2025 at 9:30 a.m. EET

The Board of Directors of Aiforia Technologies Plc has decided to launch a new stock option plan 2025D to the key employees of the company based on the authorisation given by the Annual General Meeting of Shareholders on 4 April 2025. The company has a weighty financial reason for the issue of stock options, since the stock options are intended to form part of the Company’s incentive and commitment program for the key employees. The purpose of the stock options is to encourage the key employees to work on a long-term basis in order to increase shareholder value. In addition, the stock options aim to commit the key employees to the company.

The maximum total number of stock options 2025D issued is 360,000 and they entitle their owners to subscribe for a maximum total of 360,000 new shares in the company or existing shares held by the company. The stock options are marked with the symbol 2025D.

The shares subscribed for with the stock options to be issued will account for a total maximum of 1.06 per cent of all the company's shares and votes after possible share subscriptions if new shares are issued in the subscription. As a result of the share subscriptions made with the stock options, the number of shares in the company may increase by a total maximum of 360.000 shares if new shares are issued in the subscription.

The share subscription period with stock options will be from 31 December 2026–31 December 2030 for the first third of the stock options, from 31 December 2027– 31 December 2030 for the second third of the stock options and from 31 December 2028–31 December 2030 for the last third of the stock options.

The share subscription price for the stock options 2025D is EUR 2.68 per share, which corresponds to the trade volume weighted average quotation of the Company’s share on the First North Growth Market Finland from 1 October 2025 to 30 November 2025. The share subscription price will be credited to the company's reserve for invested unrestricted equity.

The theoretical market value of one stock option 2025D is approximately EUR 0.83. The theoretical market value of the stock options 2025D is approximately EUR 298,800 in total. The theoretical market value of a stock option has been calculated by using the Black & Scholes model taking into account the subscription price of the stock option and the following input factors: share price EUR 2.25, risk-free interest rate 2.53%, validity of stock options 5 years, volatility approximately 44.7% and expected dividend yield 0%.

Further inquiries 
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358 405 009 878
https://investors.aiforia.com/

Certified Adviser 
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

 

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.

Find out more at www.aiforia.com

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.